These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 34254844)

  • 21. Mapping an Adeno-associated Virus 9-Specific Neutralizing Epitope To Develop Next-Generation Gene Delivery Vectors.
    Giles AR; Govindasamy L; Somanathan S; Wilson JM
    J Virol; 2018 Oct; 92(20):. PubMed ID: 30089698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. AAV capsid design: A Goldilocks challenge.
    Zolotukhin S; Vandenberghe LH
    Trends Mol Med; 2022 Mar; 28(3):183-193. PubMed ID: 35093287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Modification and labeling of AAV vector particles.
    Büning H; Bolyard CM; Hallek M; Bartlett JS
    Methods Mol Biol; 2011; 807():273-300. PubMed ID: 22034035
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Next-generation AAV vectors for clinical use: an ever-accelerating race.
    Weinmann J; Grimm D
    Virus Genes; 2017 Oct; 53(5):707-713. PubMed ID: 28762205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adeno-associated virus serotypes for gene therapeutics.
    Lisowski L; Tay SS; Alexander IE
    Curr Opin Pharmacol; 2015 Oct; 24():59-67. PubMed ID: 26291407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expressing Transgenes That Exceed the Packaging Capacity of Adeno-Associated Virus Capsids.
    Chamberlain K; Riyad JM; Weber T
    Hum Gene Ther Methods; 2016 Feb; 27(1):1-12. PubMed ID: 26757051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular Engineering of Adeno-Associated Virus Capsid Improves Its Therapeutic Gene Transfer in Murine Models of Hemophilia and Retinal Degeneration.
    Mary B; Maurya S; Kumar M; Bammidi S; Kumar V; Jayandharan GR
    Mol Pharm; 2019 Nov; 16(11):4738-4750. PubMed ID: 31596095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adeno-associated virus (AAV) vectors in cancer gene therapy.
    Santiago-Ortiz JL; Schaffer DV
    J Control Release; 2016 Oct; 240():287-301. PubMed ID: 26796040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A multiplexed barcode approach to simultaneously evaluate gene delivery by adeno-associated virus capsid variants in nonhuman primates.
    Stone D; Meumann N; Kuhlmann AS; Peterson CW; Xie H; Roychoudhury P; Loprieno MA; Vu XK; Strongin DE; Kenkel EJ; Haick A; Stensland L; Obenza WM; Parrott J; Nelson V; Murnane RD; Huang ML; Aubert M; Kiem HP; Büning H; Jerome KR
    Hepatol Commun; 2023 Feb; 7(2):e0009. PubMed ID: 37074875
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimization of AAV vectors to target persistent viral reservoirs.
    Colón-Thillet R; Jerome KR; Stone D
    Virol J; 2021 Apr; 18(1):85. PubMed ID: 33892762
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Engineering the AAV capsid to evade immune responses.
    Barnes C; Scheideler O; Schaffer D
    Curr Opin Biotechnol; 2019 Dec; 60():99-103. PubMed ID: 30807882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeted modifications in adeno-associated virus serotype 8 capsid improves its hepatic gene transfer efficiency in vivo.
    Sen D; Gadkari RA; Sudha G; Gabriel N; Kumar YS; Selot R; Samuel R; Rajalingam S; Ramya V; Nair SC; Srinivasan N; Srivastava A; Jayandharan GR
    Hum Gene Ther Methods; 2013 Apr; 24(2):104-16. PubMed ID: 23442071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Production, Processing, and Characterization of Synthetic AAV Gene Therapy Vectors.
    El Andari J; Grimm D
    Biotechnol J; 2021 Jan; 16(1):e2000025. PubMed ID: 32975881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Production and Chemoselective Modification of Adeno-Associated Virus Site-Specifically Incorporating an Unnatural Amino Acid Residue into Its Capsid.
    Kelemen RE; Erickson SB; Chatterjee A
    Methods Mol Biol; 2018; 1728():313-326. PubMed ID: 29405007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Receptor targeting of adeno-associated virus vectors.
    Büning H; Ried MU; Perabo L; Gerner FM; Huttner NA; Enssle J; Hallek M
    Gene Ther; 2003 Jul; 10(14):1142-51. PubMed ID: 12833123
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of Targeted Adeno-Associated Virus (AAV) Vectors for Human Gene Therapy.
    Liu Y; Siriwon N; Rohrs JA; Wang P
    Curr Pharm Des; 2015; 21(22):3248-56. PubMed ID: 26027561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent developments in adeno-associated virus vector technology.
    Büning H; Perabo L; Coutelle O; Quadt-Humme S; Hallek M
    J Gene Med; 2008 Jul; 10(7):717-33. PubMed ID: 18452237
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of the adeno-associated virus capsid in gene transfer.
    Van Vliet KM; Blouin V; Brument N; Agbandje-McKenna M; Snyder RO
    Methods Mol Biol; 2008; 437():51-91. PubMed ID: 18369962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bat adeno-associated viruses as gene therapy vectors with the potential to evade human neutralizing antibodies.
    Li Y; Li J; Liu Y; Shi Z; Liu H; Wei Y; Yang L
    Gene Ther; 2019 Jun; 26(6):264-276. PubMed ID: 31110296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthetically Engineered Adeno-Associated Virus for Efficient, Safe, and Versatile Gene Therapy Applications.
    Lugin ML; Lee RT; Kwon YJ
    ACS Nano; 2020 Nov; 14(11):14262-14283. PubMed ID: 33073995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.